Company: CRNX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0000950170-25-029050
Chunk: 4

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 16
Chunk 4
---
 common stock upon vesting of restricted stock units

    249

    —

    —

    —

    —

    Exercise of stock options

    2,294

    40,463

    —

    —

    40,463

    Stock issued under Employee Stock Purchase Plan

    222

    4,224

    —

    —

    4,224

    Stock-based compensation

    —

    69,386

    —

    —

    69,386

    Comprehensive loss

    —

    —

    (14
    )

    —

    (14
    )

    Net loss

    —

    —

    —

    (298,408
    )

    (298,408
    )

    Balance at December 31, 2024

    92,926

    $
    2,275,952

    $
    963

    $
    (952,110
    )
     
    $
    1,324,805

See the accompanying notes to these consolidated financial statements. 

F-6

CRINETICS PHARMACEUTICALS, INC.

Consolidated Statements of Cash Flows

(In thousands) 

    Year ended December 31,

    2024

    2023

    2022

    Operating activities:

    Net loss
     
    $
    (298,408
    )
     
    $
    (214,529
    )
     
    $
    (163,918
    )

    Reconciliation of net loss to net cash used in operating activities:

    Stock-based compensation

    69,386

    40,937

    28,268

    Depreciation and amortization

    2,785

    1,098

    983

    Noncash lease expense

    3,042

    1,210

    406

    Accretion of purchase discounts and amortization     of premiums on investment securities, net

    (14,931
    )

    (6,271
    )

    34

    Noncash license revenues

    —

    (2,000
    )

    —

    Loss on equity method investment

    470

    5,198

    1,010

    Loss on disposal of property and equipment

    51

    6

    —

    Change in valuation of derivative asset

    —

    —

    (600